Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 6/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25487702 | 1.00 | MEN1 (0.36) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL25487914 | 0.89 | LCK (0.35) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL25487906 | 0.89 | LCK (0.35) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL25487707 | 0.84 | GLS (0.39) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL25487700 | 0.84 | GLS (0.39) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL25487531 | 0.81 | NR3C1 (0.37) | P2RX7 | |
| SCHEMBL25487994 | 0.79 | P2RX7 (0.35) | MEN1KMT2AP2RX7 | |
| SCHEMBL25487525 | 0.77 | P2RX7 (0.36) | P2RX7 | |
| SCHEMBL17361089 | 0.77 | CCNE2 (0.36) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL22895450 | 0.75 | APP (0.37) | MEN1NPC1GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | CELGENE CAR LLC (BM) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | WEE2, WEE1, CDK2 | MEN1 1195/4885NPC1 3135/4885GAA 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.